Lentivirus targets include human and mouse ORFs

San Diego, CA -- (SBWIRE) -- 06/24/2013 -- San Diego based biotech firm GenTarget Inc has announced the availability of a wide selection of pre-made expression lentivirus targets for use by researchers. GenTarget's services include design, construction and packaging of high quality materials, as well as cell expression, cloning and generation.

Lentiviruses are used by researchers to introduce gene products to cells, typically in in vitro or in vivo animal targets, for research and study of applications such as gene therapy and RNA interference. The delicate nature of these studies calls for high quality materials delivered in a timely manner. GenTarget's lentivirus pre-made expression service gives researchers access to precisely crafted lentivirus materials with a fast turnaround time to help insure the integrity of research and results. The firm offers a wide variety of lentivirus products to suit a wide range of research needs, including lentivirus solutions for human and mouse ORFs.

GenTarget, Inc. designs sequences according to the customer's needs, constructs clones, and generates .5mL packages of ready-to-use shRNA lentivirus material. The firm also provides over-expression services based on the customer's desired target templates with options that include specific promoters, selection markers, fluorescent-target fusion, and 6His-tag at N-term or C-term for the target. In addition, the firm offers virus packaging according to the customer's lentiviral expression vector for a pre-made, ready-to-use virus with the best possible titer.

For more information about GenTarget, Inc. and its selection of pre-made expression lentivirus materials, visit http://www.gentarget.com/.

About GenTarget, Inc
Based in San Diego, California, GenTarget, Inc. is a leading biotech firm specializing in lentiviral technology and development. The firm provides high quality materials and services that researchers can rely on for precision, accuracy and quality.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

San Diego, CA -- (SBWIRE) -- 06/13/2013 -- GenTarget, Inc., the renowned US biotech company, has announced the availability of new and enhanced lentivirus production services to its suite of lentivirus solutions. The firm specializes in advanced lentiviral technology, with a long history of providing researchers with proprietary bioagents and services for use in their research. As part of its ongoing commitment to growth, expansion and advancement of research, the company has announced that it has added new and enhanced services.

Since its launch, GenTarget, Inc. has built a reputation for providing top quality services with a rapid turnaround time. The company's lentivirus offerings include the design, construction, and generation of custom shRNA; custom target expression; microRNA and anti-microRNA expression; and lentivirus design, production and packaging. These services allow researchers to draw on GenTarget, Inc's extensive experience while enjoying a "one stop" lentivirus design and production process, leaving them free to focus on the research at hand.

While GenTarget, Inc. has a long history of providing world-class lentivirus services that have been trusted by researchers around the world, the expansion and enhancement of its suite of services marks an important part of the company's strategy for growth and improvement. For more information about GenTarget, Inc. and its full range of lentivirus services, visit http://www.gentarget.com/.

About GenTarget, Inc.
Since 2008, GenTarget, Inc. has built a reputation as a pioneer in the field of lentiviral technology. Led by a scientist with more than two decades of experience in biomedical research and backed by a world-class staff, the company works to provide the best solutions for researchers in order to advance stem cell research, drug discovery and other biological investigation.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm